Leerink Partners Cuts Price Target on Wright Medical Group (WMGI) Following 3Q

November 3, 2016 7:22 AM EDT
Get Alerts WMGI Hot Sheet
Price: $23.64 +2.43%

Rating Summary:
    19 Buy, 10 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade WMGI Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Leerink Partners maintained an Outperform rating on Wright Medical Group (NASDAQ: WMGI), and cut the price target to $25.00 (from $27.00), following the company's 3Q earnings report. Revenue from continuing operations of $157.3M was about in-line with consensus' $157.7M. EBITDA of $5.7M beat the consensus estimate of $3M.

Analyst Richard Newitter commented, "WMGI's 3Q saw another solid EBITDA beat (and guidance raise) on in-line sales, and WMGI reiterated its full-year rev. outlook (at the midpoint of narrowed guidance). Moreover, a final metal-on-metal (MoM) litigation settlement was reached--in-line with the range mgmt had previously disclosed in 2Q--which should help remove a stock overhang. We reiterate our OP rating with a view that: (1) WMGI/TRNX remains an attractive mid-cap growth extremities/ biologics asset with broad reach across three of the fastest-growing ortho markets (shoulder, foot & ankle, biologics) with ramping/inflecting EBITDA margin; (2) upper/lower extremities end-market growth remains healthy & WMGI's share gain prospects within them is strong. Our PT goes to $25 (vs. $27) based on recent multiple compression for the group."

For an analyst ratings summary and ratings history on Wright Medical click here. For more ratings news on Wright Medical click here.

Shares of Wright Medical closed at $20.78 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Earnings

Add Your Comment